AddedRisk Factors
Additionally, we have evaluated, and will continue to evaluate, potential relationships with additional suppliers to increase overall capacity as well as further reduce risks associated with reliance on a limited number of suppliers for manufacturing.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
Certain of our pharmaceutical products are manufactured outside of the United States. Recently, the U.S. government has initiated substantial changes in U.S. trade policy and U.S. trade agreements, including the initiation of tariffs on certain foreign goods, and has indicated an intention to impose tariffs on imported pharmaceutical products. In response to these tariffs, foreign governments have instituted or are considering imposing tariffs on certain U.S. goods, in addition to other retaliatory measures. If the U.S. imposes additional tariffs or other trade measures on pharmaceutical products, and in response other countries take further retaliatory trade measures, these actions could impose additional costs on our business.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
The One Big Beautiful Bill Act, which was enacted in July 2025, imposes significant reductions in the funding of the Medicaid program. Such reductions are expected to decrease the number of persons enrolled in Medicaid and reduce the services covered by Medicaid, which could adversely affect our sales of IMCIVREE or any other product candidate that we commercialize.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
The Trump administration is pursuing a two-fold strategy to reduce drug costs in the U.S. While it is unclear whether and how the Trump proposals will be implemented, the Trump policies are likely to have a negative impact on the pharmaceutical industry and on our ability to receive adequate revenues for IMCIVREE. On the one hand, President Trump has threatened to impose significant tariffs on pharmaceutical manufacturers that do not adopt pricing policies such as most favored nation pricing, which would tie the price for drugs in the U.S. to the lowest price in a group of other countries. In response, multiple manufacturers have reportedly entered into confidential pricing agreements with the federal government. On the other hand, the Trump administration is pursuing traditional regulatory pathways to impose drug pricing policies, and published two proposed regulations in December 2025, referred to as Globe and Guard. If finalized, these regulations would implement mandatory payment models under which manufacturers of eligible drugs would be required to pay rebates to the federal government on a portion of the units of their drugs that are reimbursed by Medicare, with the rebate amount based on most favored nation pricing. Imposing a rebate in the U.S. that is based on drug prices outside the U.S. would mark a drastic and unprecedented shift in the U.S. pharmaceutical market, and while the impact of the Globe and Guard proposed regulations, if finalized, cannot yet be determined, it is likely to be significant. Even regulatory proposals or executive actions that are ultimately deemed unlawful could negatively impact the U.S. pharmaceutical sector and our business. In addition, pharmaceutical pricing and marketing has long been the subject of considerable discussion in
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RemovedRisk Factors
From August 2015 through August 2017, we raised aggregate net proceeds of $80.8 million through our issuance of series A preferred stock. In connection with our initial public offering, or IPO, in October 2017 and our underwritten follow-on offerings through December 2024, we raised aggregate net proceeds of approximately $832.7 million through the issuance of our common stock after deducting underwriting discounts, commissions and offering related transaction costs. We received a further $100.0 million from asset sales, specifically in connection with the sale of our Rare Pediatric Disease Priority Review Voucher, or PRV, to Alexion Pharmaceuticals, Inc. In June 2022, we entered into a Revenue Interest Financing Agreement, or RIFA, with HealthCare Royalty Partners for a total investment amount of up to $100.0
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
costs, following the achievement of a specified amount of cumulative net sales of IMCIVREE between July 1, 2022 and September 30, 2023.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
It is currently unclear to what extent the United Kingdom will seek to align its regulations with the EU. On January 17, 2022, the MHRA launched an eight-week consultation on reframing the UK legislation for clinical trials and which aimed to streamline clinical trials approvals, enable innovation, enhance clinical trials transparency, enable greater risk proportionality, and promote patient and public involvement in clinical trials. The UK Government published its response to the consultation on March 21, 2023 confirming that it would bring forward changes to the legislation. These resulting legislative amendments will determine how closely the UK regulations are aligned with the CTR. A decision by the UK not to closely align its regulations with the new approach adopted in the EU may have an effect on the cost of conducting clinical trials in the UK as opposed to other countries. Under the terms of the Protocol on Ireland/Northern Ireland, provisions of the CTR which relate to the manufacture and import of investigational medicinal products and auxiliary medicinal products apply in Northern Ireland. Once the changes brought by the Windsor Framework are implemented, this may have a further impact on the application of the CTR in Northern Ireland.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
Grant of orphan designation by the EC also entitles the holder of this designation to financial incentives such as reduction of fees or fee waivers, protocol assistance, and access to the centralized marketing authorization procedure. In
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
In the EU, until May 25, 2022, in vitro diagnostic medical devices were regulated by Directive 98/79/EC, or the IVDD, which has been repealed and replaced by Regulation (EU) No 2017/746, or the IVDR. Unlike the IVDD, the IVDR is directly applicable in EU member states without the need for member states to implement into national law. The
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
violations of FDA rules and regulations and the comparable foreign regulatory provisions during the conduct of our clinical trials. Outside parties may:
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
The commercial success of IMCIVREE will also depend upon the awareness and acceptance of IMCIVREE within the medical community, including physicians, patients and third-party payors. If IMCIVREE does not achieve or
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
Currently, IMCIVREE is the only treatment approved to reduce excess body weight and maintain weight reduction long term in patients with obesity due to BBS or POMC, PCSK1 or LEPR deficiencies, and there are no comparable treatments approved for patients with deficiencies due to a variant in one of the two alleles in the POMC, PCSK1, or LEPR genes (HET obesity), SRC1 deficiency obesity, SH2B1 deficiency obesity, MC4R deficiency obesity, and hypothalamic obesity. Bariatric surgery is often not considered an appropriate treatment option for these genetic diseases of obesity because the severe obesity and hyperphagia associated with these diseases are considered to be risk factors for poor outcomes with bariatric surgery. Also, existing therapies indicated for general obesity, including glucagon-like peptide-1 (GLP-1) receptor agonists, and glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) agonists, do not specifically restore function impaired by genetic deficiencies in the MC4R pathway, which we believe is the root cause of hyperphagia and obesity in patients with MC4R genetic variants. At present, we are aware of multiple ongoing research and development programs for general obesity with various new mechanisms of action including some MC4R agonists. New competitors may emerge which could limit our business opportunity in the future.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
ourselves against them, we could incur substantial liabilities. In addition, regardless of merit or eventual outcome, product liability claims may result in, among other things:
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
which could significantly impact the global supply chain for setmelanotide, RM-718, and bivamelagon. With the exception of those on the FDA’s drug shortage list or properly imported by individuals, the FDCA prohibits the importation of prescription drug products for commercial use if they were manufactured in a foreign country, unless they have been approved or are otherwise authorized to be marketed in the United States and are labeled accordingly.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
to support all of our current needs for clinical trial and initial commercial supplies for setmelanotide, RM-718, and bivamelagon, if approved. Going forward, we may need to identify additional CMOs or partners to produce setmelanotide, RM-718, and bivamelagon on a larger scale.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
In light of our election to terminate the exclusive license agreement with RareStone Group Ltd., or RareStone, the development of setmelanotide in certain indications and commercialization of IMCIVREE in certain markets could be delayed or terminated and our business could be adversely affected.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RewordedRisk Factors
For example, in Europe, we are subject to the European Union General Data Protection Regulation (“EU GDPR”) and to the United Kingdom General Data Protection Regulation and Data Protection Act 2018 (collectively, the “UK GDPR”) (the EU GDPR and UK GDPR together referred to as the “GDPR”) The GDPR became effective on May 25, 2018, and imposes strict requirements for the processing of the personal data of individuals within the European Economic Area, or EEA, and the UK or in the context of our activities in the EEA, EEA or UK, including health data from clinical trials and AE reporting.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Despite our efforts, from time to time we may not be able to conclude that our internal control over financial reporting is effective as required by Section 404, as was the case for the year ended December 31, 2023 and quarterly periods in 2024, due to a material weakness identified in internal controls related to ineffective information technology general controls in the areas of user access and program change management over our key accounting and reporting information technology system. 404.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our failure to comply with our obligations under the GDPR or UK GDPR, including any failure to adopt measures to ensure that we can continue to conduct the data processing activities that we initiated in the EU before the GDPR entered into application, the UK GDPR, and other countries’ privacy or data security-related laws could adversely impact our ability to use the data generated in our studies.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
For example, in November 2020, IMCIVREE is currently approved by the FDA approved IMCIVREE for chronic weight management use in adult adults and pediatric patients 6 two years of age and older with syndromic or monogenic obesity due to BBS and due to POMC, PCSK1, or LEPR deficiencies confirmed as determined by genetic testing a companion diagnostic demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
If the FDA or a comparable regulatory authority requires clearance, approval or certification of a companion diagnostic when we seek additional approvals for setmelanotide, RM-718 or bivamelagon, any Any delay or failure by us or our current and or future collaborators to develop or obtain regulatory clearance or approval of, or certification of, such tests, if and when necessary, could delay or prevent us from obtaining such additional approvals for setmelanotide, or adversely affect the approvals we have already obtained.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
We have entered into process development and manufacturing service agreements with our CMOs, Corden Pharma Switzerland, LLC, (formerly Recipharm), or Corden, (formerly Peptisyntha SA prior to its acquisition by Corden), and Neuland Laboratories Astrea, for certain process development and manufacturing services for regulatory starting materials and/or raw materials in connection with the manufacture of setmelanotide.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Successful completion of our ongoing and planned clinical trials is a prerequisite to submitting an NDA or NDA supplement to the FDA, an MAA a marketing authorization application (“MAA”) to the EMA, and other applications for marketing authorization to equivalent competent authorities in foreign jurisdictions, and consequently, successful completion of such trials, at a minimum, will be required for regulatory approvals and the commercial marketing of setmelanotide for additional indications as well as RM-718 and bivamelagon.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing amount of focus on privacy and data protection issues with the potential to affect our business, including recently enacted laws in a majority of states every state requiring security breach notification, some also require implementation of reasonable security measures and provide a private right of action in the event of a breach. notification.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
We could also be required to seek funds through arrangements with collaborative partners or other third parties at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to setmelanotide or technologies or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Foreign sales of setmelanotide could also be adversely affected by the imposition of governmental controls, political and economic instability, trade restrictions and changes in tariffs. tariffs, including the imposition of tariffs by the United States or any other tariffs that could apply directly or indirectly to the costs of goods required to manufacture setmelanotide.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Pursuant to the terms of the license agreement, we obtained exclusive worldwide rights to develop LGC’s proprietary compound bivamelagon and assumed sponsorship of two ongoing LGC Phase 2 studies designed to evaluate safety, tolerability, pharmacokinetics and weight loss efficacy of bivamelagon, one of which remains ongoing. bivamelagon.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
If a prolonged government shutdown occurs, or if global health concerns policy changes, funding shortages or staffing limitations or any other disruptions prevent or hinder the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it including providing us with advice on our development programs in a timely manner, such events could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
We will expect we may need to raise additional funding, which may not be available on acceptable terms, or at all.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
However, our Our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings, government or other third-party funding, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements, or a combination of these approaches.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Each of the four sub-studies will be is entirely independent of the others and, if successful, is designed to support separate regulatory submissions to the FDA and EMA in each studied population.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Our addressable patient population estimate for hypothalamic obesity (HO) is 5,000 to approximately 10,000 patients in the United States.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
The Medicare Part D rebate rebate, if applicable, will be calculated on the basis of the AMP figures we report pursuant to the MDRP.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
We have put into place certain safeguards with technology, process and education to mitigate the risks inherent in our information technology systems and to defend against cyberattacks and security incidents.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
Following our disclosure in December 2025 of positive preliminary data from our ongoing, exploratory, open-label Phase 2 trial with setmelanotide in patients with PWS, we believe there is potential for an MC4R agonist to be a future treatment option for patients with PWS, a rare genetic disorder that results in a number of physical, mental and behavioral problems. A key feature of PWS is a constant sense of hunger that usually begins in early childhood. PWS is estimated to affect approximately 400,000 people worldwide and approximately 20,000 people in the United States. There are currently limited therapeutic options that effectively reduce the extreme hyperphagia and address low resting energy expenditure associated with PWS. Following the disclosure of these positive preliminary results in December 2025, we announced plans to further develop setmelanotide and RM-718 for PWS.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
consideration of the available facts and circumstances. As of December 31, 2025, we did not have any uncertain tax positions.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
License revenue. During the year ended December 31, 2025, we recognized a reduction of previously recognized license revenue of $5.0 million in connection with the termination of our exclusive license agreement with RareStone. See Note 10, Significant Agreements, in the consolidated financial statements.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
•an increase of $7.2 million associated with chemistry, manufacturing, and controls (CMC) costs for drug formulation and autoinjector development to support RM-718 and our ongoing Phase 1 clinical trial of RM-718.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
the sale of the shares pursuant to the offering, including the shares sold pursuant to the exercise in full of the option, took place on July 11, 2025, resulting in net proceeds of approximately $188.7 million, net of $12.6 million of underwriting discounts and commissions, and other offering expenses that we incurred, for a total share issuance of 2,367,647.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RemovedMD&A
In addition to setmelanotide, we have two earlier-stage investigational MC4R agonists in clinical development, RM-718, designed for weekly administration, and bivamelagon, an oral small molecule, which are each advancing in Phase 1 and 2 clinical trials, respectively. These investigational assets are designed to be highly selective for the MC4R and MC1R sparing and thereby not cause hyperpigmentation. We completed enrollment in our Phase 2 trial evaluating bivamelagon, in acquired hypothalamic obesity in the first quarter of 2025. With RM-718, we anticipate initiating Part C of our Phase 1 trial to evaluate this weekly MC4R agonist in patients with acquired hypothalamic obesity in the first quarter of 2025.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
We are leveraging what we believe is the largest known DNA database focused on obesity - with approximately 100,000 sequencing samples as of December 31, 2024 - to improve the understanding, diagnosis and care of people living
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
We are developing setmelanotide to address additional patients with acquired hypothalamic obesity. In our Phase 2 trial evaluating setmelanotide as a treatment for hypothalamic obesity, as announced in November 2022, 16 of 18 patients achieved the primary endpoint with a body mass index (BMI) decrease greater than 5 percent on setmelanotide therapy, and we observed a 14.5 mean percent reduction in BMI across all patients. As part of our November 2022 presentation, we detailed that fourteen of these patients transitioned from this Phase 2 trial into our open-label, long-term extension trial and they remained on therapy, as of November 3, 2023. Twelve of these 14 patients had achieved a 25.5% reduction in mean BMI from baseline at one year on setmelanotide therapy. On February 22, 2024, we provided an update on progress of our pivotal, Phase 3 clinical trial evaluating setmelanotide in patients with acquired hypothalamic obesity. We completed enrollment in the Phase 3 clinical trial is designed to enroll 120 patients aged 4 years or older randomized 2:1 to setmelanotide therapy or placebo for a total of 60 weeks, including up to eight weeks for dose titration. The primary endpoint is the percent change in BMI after approximately 52 weeks on a therapeutic regimen of setmelanotide versus placebo. Key secondary endpoints include the proportion of patients who achieve ≥5% reduction in BMI from baseline in adults (≥18) or BMI Z-score reduction of ≥0.2 from baseline in pediatrics after approximately 52 weeks on a therapeutic regimen of compared with placebo, and mean change in the weekly average of the daily most hunger score in patients ≥12 years from baseline after approximately 52 weeks on a therapeutic regimen of setmelanotide versus placebo. We expect to report top-line study results in the first half of 2025.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
To date, we have not generated sufficient cash flow from product sales and have financed our operations primarily through the proceeds received from the sales of common and preferred stock, royalty interest financing, asset sales, as well as capital contributions from the former parent company, Rhythm Holdings LLC. From August 2015 through August 2017, we raised aggregate net proceeds of $80.8 million through our issuance of Convertible Preferred Stock (as defined below). Since our initial public offering, or IPO, on October 10, 2017 and our underwritten follow-on offerings through October 2022, we have raised aggregate net proceeds of approximately $832.7 million through the issuance of our common stock after deducting underwriting discounts, commissions and offering related transaction costs. We also received $100.0 million from the sale of our Rare Pediatric Disease Priority Review Voucher, or PRV, to Alexion Pharmaceuticals, Inc. in February 2021. In June 2022, we entered into the Revenue Interest Financing Agreement (“RIFA”), with entities managed by HealthCare Royalty Partners, collectively referred to as the Investors, and through December 31, 2024 have received cumulative proceeds of $96.7 million, net of certain transaction costs. We also received $147.8 million in net proceeds under the Investment Agreement, with certain affiliates of Perceptive Advisors LLC, or Perceptive, and certain other investors, relating to the issuance and sale of 150,000 shares of a new series of the Company’s Series A Convertible Preferred Stock, par value $0.001 per share, titled the “Series A Convertible Preferred Stock”, or the Convertible Preferred Stock, for an aggregate purchase price of $150.0 million, or $1,000 per share. As of December 31, 2024, our cash and cash equivalents and short-term investments were approximately $320.6 million. We expect that our existing cash and cash equivalents and short-term investments will be sufficient to fund our operations into 2027.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
activity due to the completion and wind down of our long term extension trial, Phase 2 Basket trial, Phase 3 pediatrics trial, and switch trial; and
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
an increase of $4.3 million due to increased CMC development costs related to RM-718 and bivamelagon.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
a decrease in our clinical trial costs associated with decreased activity in our Phase 2 DAYBREAK trial and pediatrics trial for setmelanotide therapy of approximately $3.6 million.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
a decrease in inventoriable costs that were capitalized to inventory as labor and overhead, of $1.7 million.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
an increase in interest income of $0.8 million earned on our short-term investments, based on higher investment balances from the net proceeds of $147.8 million from the convertible preferred stock issuance.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
recognition of $4.0 million of non-cash interest expense in 2024 associated with accretion of the current liability payable to LGC in July 2025; and
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
an increase in non-cash interest expense of $2.7 million related to amortization of debt discount and deferred financing fees associated with our higher deferred royalty obligation balance, based on the receipt of our final $25.0 million sales milestone in the three months ended September 30, 2023.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
investments of $354.9 million were generally offset by gross proceeds from maturities of short-term investments of $355.0 million.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RewordedMD&A
Net cash used in operating activities was $113.9 $115.7 million for the year ended December 31, 2024, 2025, and consisted primarily of a net loss of $260.6 $196.5 million adjusted for $81.8 million of non-cash items of $43.8 million, charges, which consisted of stock-based compensation, depreciation and amortization, non-cash interest expense, non-cash accretion and amortization of short-term investments, non-cash accretion of other current liability, non-cash rent expense, gain on settlement of forward contract, and the change in the fair value of our embedded derivative liability. liability, which we expect to continue to have these add-backs to net income.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Based on our current development plans as of December 31, 2024, 2025, we expect to make a $2.0 million milestone payments payment to third parties, during the next 12 months from sellers of Xinvento upon the filing commencement of this Annual Report. good laboratory practices toxicity trials (currently expected to begin in 2026).
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Under the terms of the LG Chem license agreement, we have paid LG Chem $40 $80 million in cash, cash and issued shares to them of our common stock with an aggregate value of $20 million and agreed to make a $40 million payment in cash 18 months after the effective date of the license agreement. million.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Following these approvals for BBS, initial approvals, sales of IMCIVREE have grown, and we expect will continue to grow as we identify and treat more patients with this disease and obtain reimbursement throughout the international markets in which we operate. grow.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Product revenue, net increased by $52.7 $64.6 million to $194.8 million in 2025 from $130.1 million in 2024 from $77.4 million in 2023, 2024, an increase of 68%. 50%, due primarily to higher volume of product sold both domestically and internationally.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Net cash provided by financing activities was $191.2 $218.0 million for the year ended December 31, 2024, and 2025, which consisted of net proceeds of $147.8 $188.7 million from the issuance a follow-on offering of Convertible Perferred Stock as well as our common stock in July 2025, and net proceeds from our ATM equity offering of $39.1 $34.0 million.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
IMCIVREE, an our most advanced MC4R agonist for which we hold worldwide rights, is the first-ever therapy developed for patients with certain rare diseases that is approved or authorized marketed in the United States, European Union (EU), United Kingdom, Canada and several other countries and regions. regions for certain rare MC4R pathway diseases, including BBS.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Net cash used in investing activities was $48.2 $137.2 million for the year ended December 31, 2024 2025 and related to purchases of short term investments for $268.3 $348.7 million and cash used for the purchase of final payment we made in July 2025 for LGC’s proprietary compound bivamelagon for $40.0 million in January 2024, million, offset by gross maturities and sales of short-term investments of $260.6 $252.5 million.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
In addition, under the terms of the Underwriting Agreement, we granted the underwriters Underwriters a 30-day option to purchase up to an 308,823 additional 720,000 shares of its common stock Common Stock, at the public offering price to the public, per share, less underwriting discounts and commissions.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Research and development expense increased decreased by $103.0 $70.6 million to $167.3 million in 2025 from $238.0 million in 2024 from $135.0 million in 2023, an increase 2024, a decrease of 76%. 30%.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
We expect our sales of IMCIVREE to continue to increase following the FDA approval for the treatment of patients with BBS in the United States in June 2022. increase.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
In April 2024, we received $147.8 million in net proceeds under the Investment Agreement, with certain affiliates of Perceptive Advisors LLC, or Perceptive, and certain other investors, relating to the issuance and sale of 150,000 shares of a new series of the Company’s Convertible Preferred Stock for an aggregate purchase price of $150.0 million, or $1,000 per share. share - see Note 9 to our consolidated financial statements - Series A Convertible Preferred Stock for additional information.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesMD&A
If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new